Results 181 to 190 of about 516,620 (290)

Changes in Hypertrophic Synovium Status in Adult Patients With Severe Hemophilia A Receiving Emicizumab Prophylaxis: The RESOLVE Study

Haemophilia, EarlyView.
ABSTRACT Background Evidence on the impact of emicizumab on joint health, particularly hypertrophic synovium (HS), remains limited. Objectives To evaluate changes in HS, using point‐of‐care ultrasound and clinical examination in People with Haemophilia (PwH) switching from replacement therapy to emicizumab.
Matteo Nicola Dario Di Minno, Erminia Baldacci, Ilenia Lorenza Calcaterra, Guido D'Errico, Cristina Santoro, Alessandra Strangio, Silvia Sorella, Marzia Leotta, Rita Carlotta Santoro   +8 more
wiley   +1 more source

Generation of an NG2 targeting bispecific antibody for the induction of T-cell immunity against melanoma. [PDF]

J Transl Med
Prakash N, Hörner S, Hagelstein I, Keller J, Wang K, Jung G, Salih HR, Lutz MS.   +7 more
europepmc   +1 more source

Patient Perspectives in Haemophilia A: Unmet Needs of Individuals Receiving Factor and Non‐Factor Treatments

Haemophilia, EarlyView.
ABSTRACT Introduction There is limited qualitative published real‐world data on treatment patterns among people with severe haemophilia A (PwSHA), particularly those with unmet needs. Aim This qualitative study aimed to explore the impact of taking prophylactic extended half‐life factor VIII (EHL‐FVIII) or emicizumab on psychosocial and physical ...
Nana Kragh, Veruska Carboni, Duygu Bozkaya, Idaira Rodriguez‐Santana, Claudia Mighiu, Bethany Franks, Arnoud Plat, Randall Curtis   +7 more
wiley   +1 more source

Durable CNS remission with elranatamab and intrathecal therapy in relapsed/refractory multiple myeloma. [PDF]

Ann Hematol
Mersin S, Sevindik ÖG.
europepmc   +1 more source

Comparison of intestinal histopathological changes following teclistamab, BCMA‐directed CAR T, CD19‐directed CAR T and rituximab therapies

Histopathology, EarlyView.
This is a retrospective review of intestinal tract biopsies from patients treated with various cellular immunotherapies (BCMA and CD19‐directed CAR T, teclistamab and rituximab therapies). We found distinct but overlapping histologic patterns across treatment groups, with lamina propria plasma cell depletion, crypt apoptotic bodies and active ...
Olivia J Leung, Esther Baranov, Isairis Peralta Valerio, Robin Collingwood, Natalie Respond, Don Siegel, Pooja Devi, Kristen M. Stashek   +7 more
wiley   +1 more source

An IgG-like fusion protein comprising an anti-spike S2 antibody and ACE2 exhibits potent and broad neutralization against SARS-CoV-2 and variants of concern. [PDF]

Antib Ther
Wei Z, Liu X, Wang K, Chen L, Xiao X, Sun Y, Wang W, Chen Y, Fang L, Qi Y, Yang F, Hao X, Fan R, Zheng S, Ren L, Li W, Tian X, Sui J.   +17 more
europepmc   +1 more source

Radiotherapy in Combination with CD20×CD3 Bispecific Antibodies for B-Cell Lymphoma: Biological Rationale, Current Evidence, and Open Questions. [PDF]

Cancers (Basel)
Ciammella P, Bavieri A, Nizzoli ME, Alì E.   +3 more
europepmc   +1 more source

A PD1‐CD137L Fusion Protein More Potently Enhances Anti‐Tumour Immune Responses Than Targeting PD‐L1 and CD137 Separately

Immunology, EarlyView.
A PD1‐CD137L fusion protein converts the immunoinhibitory PD‐L1 to an immunostimulatory signal and is more effective than targeting PD‐L1 and CD137 separately. ABSTRACT Tumour immune evasion frequently involves PD‐L1‐mediated inhibition of T cell activity, limiting the efficacy of PD1/PD‐L1 blockade, particularly in PD‐L1‐low or immunologically ‘cold ...
Runze Xia, Emily Pauline Nickles, Yu Mei, Thamizhanban Manoharan, Yi Tian Png, Beijia Liu, Rui Sun, Kang Yi Lee, Gloryn Chia, Chwee Ming Lim, Herbert Schwarz   +10 more
wiley   +1 more source

Advances in Bispecific Antibodies and Antibody-Drug Conjugates for Colorectal Cancer Treatment. [PDF]

Antibodies (Basel)
Cappellino MG, Sullivan SP, High PC, Blackburn TA, Carmon KS.   +4 more
europepmc   +1 more source

Pathophysiology and emerging treatments for dermographic, cholinergic and cold urticaria

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This review illustrates key proposed mast cell‐mediated activation pathways in dermographic, cholinergic and cold urticaria, highlighting IgE‐dependent and ‐independent mechanisms. These pathways are increasingly targeted by emerging drugs, aiming to interrupt mast cell activation and mediator release, offering more precise, mechanism‐based treatment ...
Mojca Bizjak‐Suran, Matjaž Fležar, Manuel Pedro Pereira   +2 more
wiley   +1 more source